Table 1.
Baseline clinical and demographic characteristics of the cohort of overweight or obese type 2 diabetes (T2D) patients eligible for the primary analysis (N = 126) with at least one prescription of dulaglutide 1.5 mg/once weekly as add-on to metformin (MET) or MET plus conventional insulin secretagogues.
| Clinical and Demographic Characteristics | N or Means % or (SD) | |
|---|---|---|
| Female gender, N | 61 | 48.4% |
| Age, yr | 59.8 | (9.4) |
| T2D duration, yr | 8.0 | (6.0) |
| T2D duration >10 yr | 41 | 32.5% |
| Hypertension, N | 97 | 77.0% |
| CHD, N | 11 | 8.7% |
| History of stroke/TIA, N | 4 | 3.2% |
| Peripheral arterial disease, N | 2 | 1.6% |
| Overweight (BMI 25–29.9 kg/m2), N | 46 | 36.5% |
| Obesity (BMI ≥ 30 kg/m2), N | 80 | 63.5% |
| Dyslipidemia, N | 76 | 60.3% |
| Other comorbidities, N | 86 | 68.3% |
| Microvascular diabetic complications, N | 23 | 18.3% |
| Diabetic retinopathy, N | 9 | 7.1% |
| Early-stage DKD, N | 8 | 6.4% |
| Advanced stage DKD, N | 1 | 0.8% |
| Diabetic neuropathy, N | 9 | 7.1% |
| Background Medications | ||
| ACE inhibitors, N | 34 | 27.0% |
| ARB, N | 42 | 33.3% |
| Calcium blockers, N | 15 | 11.9% |
| Beta-blockers, N | 37 | 29.4% |
| Diuretics, N | 46 | 36.5% |
| Alpha1 blockers, N | 7 | 5.6% |
| Statin, N | 59 | 46.8% |
| Ezetimibe, N | 6 | 4.8% |
| Cardioaspirin, N | 23 | 18.3% |
| Other medications, N | 45 | 35.7% |
| MET, N | 126 | 100% |
| MET plus sulfonylurea, N | 18 | 14.2% |
| MET plus glinide, N | 9 | 7.1% |
| Naïve to GLP-1 RAs, N | 109 | 86.5% |
Data are presented as N and %, or means (SD), as appropriate. CHD: coronary heart disease; TIA: transient ischemic attack; DKD: diabetic kidney disease; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers; GLP-1 RA: GLP-1 receptor agonist; SD: standard deviations; BMI: body mass index.